740 related articles for article (PubMed ID: 16186187)
1. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells.
Ko K; Yamazaki S; Nakamura K; Nishioka T; Hirota K; Yamaguchi T; Shimizu J; Nomura T; Chiba T; Sakaguchi S
J Exp Med; 2005 Oct; 202(7):885-91. PubMed ID: 16186187
[TBL] [Abstract][Full Text] [Related]
2. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals.
Mitsui J; Nishikawa H; Muraoka D; Wang L; Noguchi T; Sato E; Kondo S; Allison JP; Sakaguchi S; Old LJ; Kato T; Shiku H
Clin Cancer Res; 2010 May; 16(10):2781-91. PubMed ID: 20460483
[TBL] [Abstract][Full Text] [Related]
3. Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells.
Fecci PE; Sweeney AE; Grossi PM; Nair SK; Learn CA; Mitchell DA; Cui X; Cummings TJ; Bigner DD; Gilboa E; Sampson JH
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4294-305. PubMed ID: 16857805
[TBL] [Abstract][Full Text] [Related]
4. A key regulatory role of the transcription factor NFATc2 in bronchial adenocarcinoma via CD8+ T lymphocytes.
Maxeiner JH; Karwot R; Sauer K; Scholtes P; Boross I; Koslowski M; Türeci O; Wiewrodt R; Neurath MF; Lehr HA; Finotto S
Cancer Res; 2009 Apr; 69(7):3069-76. PubMed ID: 19318584
[TBL] [Abstract][Full Text] [Related]
5. Transient attenuated Foxp3 expression on CD4⁺ T cells treated with 7D4 mAb contributes to the control of parasite burden in DBA / 2 mice infected with lethal Plasmodium chabaudi chabaudi AS.
Feng H; Zhu XT; Qi ZM; Wang QH; Wang GG; Pan YY; Li Y; Zheng L; Jiang YJ; Shang H; Cui L; Cao YM
Scand J Immunol; 2012 Jan; 75(1):46-53. PubMed ID: 21916916
[TBL] [Abstract][Full Text] [Related]
6. In vivo expansion of CD4+Foxp3+ regulatory T cells mediated by GITR molecules.
Nishioka T; Nishida E; Iida R; Morita A; Shimizu J
Immunol Lett; 2008 Dec; 121(2):97-104. PubMed ID: 18930767
[TBL] [Abstract][Full Text] [Related]
7. Mature B cells are critical to T-cell-mediated tumor immunity induced by an agonist anti-GITR monoclonal antibody.
Zhou P; Qiu J; L'Italien L; Gu D; Hodges D; Chao CC; Schebye XM
J Immunother; 2010 Oct; 33(8):789-97. PubMed ID: 20842058
[TBL] [Abstract][Full Text] [Related]
8. Combinations of tumor-specific CD8+ CTLs and anti-CD25 mAb provide improved immunotherapy.
Ohmura Y; Yoshikawa K; Saga S; Ueda R; Kazaoka Y; Yamada S
Oncol Rep; 2008 May; 19(5):1265-70. PubMed ID: 18425386
[TBL] [Abstract][Full Text] [Related]
9. In vivo ligation of glucocorticoid-induced TNF receptor enhances the T-cell immunity to herpes simplex virus type 1.
La S; Kim E; Kwon B
Exp Mol Med; 2005 Jun; 37(3):193-8. PubMed ID: 16000873
[TBL] [Abstract][Full Text] [Related]
10. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance.
Shimizu J; Yamazaki S; Takahashi T; Ishida Y; Sakaguchi S
Nat Immunol; 2002 Feb; 3(2):135-42. PubMed ID: 11812990
[TBL] [Abstract][Full Text] [Related]
11. Naloxone can improve the anti-tumor immunity by reducing the CD4+CD25+Foxp3+ regulatory T cells in BALB/c mice.
Molla Hassan AT; Hassan ZM; Moazzeni SM; Mostafaie A; Shahabi S; Ebtekar M; Hashemi SM
Int Immunopharmacol; 2009 Nov; 9(12):1381-6. PubMed ID: 19706340
[TBL] [Abstract][Full Text] [Related]
12. Murine bone marrow chimeras developing autoimmunity after CTLA-4-blockade show an expansion of T regulatory cells with an activated cytokine profile.
De Somer L; Fevery S; Bullens DM; Rutgeerts O; Lenaerts C; Mathieu C; Boon L; Kasran A; Waer M; Billiau AD
Immunol Lett; 2010 Sep; 133(1):49-53. PubMed ID: 20600326
[TBL] [Abstract][Full Text] [Related]
13. Administration of anti-CD25 mAb leads to impaired α-galactosylceramide-mediated induction of IFN-γ production in a murine model.
Rosalia RA; Štěpánek I; Polláková V; Šímová J; Bieblová J; Indrová M; Moravcová S; Přibylová H; Bontkes HJ; Bubeník J; Sparwasser T; Reiniš M
Immunobiology; 2013 Jun; 218(6):851-9. PubMed ID: 23182710
[TBL] [Abstract][Full Text] [Related]
14. Interference with CD4+CD25+ T-cell-mediated tolerance to experimental autoimmune thyroiditis by glucocorticoid-induced tumor necrosis factor receptor monoclonal antibody.
Morris GP; Kong YC
J Autoimmun; 2006 Feb; 26(1):24-31. PubMed ID: 16253477
[TBL] [Abstract][Full Text] [Related]
15. Identification and characterization of Foxp3(+) gammadelta T cells in mouse and human.
Kang N; Tang L; Li X; Wu D; Li W; Chen X; Cui L; Ba D; He W
Immunol Lett; 2009 Aug; 125(2):105-13. PubMed ID: 19539651
[TBL] [Abstract][Full Text] [Related]
16. Induction of antigen-specific immunologic tolerance by in vivo and in vitro antigen-specific expansion of naturally arising Foxp3+CD25+CD4+ regulatory T cells.
Nishimura E; Sakihama T; Setoguchi R; Tanaka K; Sakaguchi S
Int Immunol; 2004 Aug; 16(8):1189-201. PubMed ID: 15237110
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic glucocorticoid-induced TNF receptor-mediated amplification of CD4+ T cell responses enhances antiparasitic immunity.
Haque A; Stanley AC; Amante FH; Rivera Fde L; Zhou Y; Kuns RD; Yardley V; Sakaguchi S; Hill GR; Engwerda CR
J Immunol; 2010 Mar; 184(5):2583-92. PubMed ID: 20139272
[TBL] [Abstract][Full Text] [Related]
18. IL-2 contributes to maintaining a balance between CD4+Foxp3+ regulatory T cells and effector CD4+ T cells required for immune control of blood-stage malaria infection.
Berretta F; St-Pierre J; Piccirillo CA; Stevenson MM
J Immunol; 2011 Apr; 186(8):4862-71. PubMed ID: 21389253
[TBL] [Abstract][Full Text] [Related]
19. Suppression of Tregs by anti-glucocorticoid induced TNF receptor antibody enhances the antitumor immunity of interferon-α gene therapy for pancreatic cancer.
Aida K; Miyakawa R; Suzuki K; Narumi K; Udagawa T; Yamamoto Y; Chikaraishi T; Yoshida T; Aoki K
Cancer Sci; 2014 Feb; 105(2):159-67. PubMed ID: 24289533
[TBL] [Abstract][Full Text] [Related]
20. Tumor-specific crosslinking of GITR as costimulation for immunotherapy.
Burckhart T; Thiel M; Nishikawa H; Wüest T; Müller D; Zippelius A; Ritter G; Old L; Shiku H; Renner C
J Immunother; 2010; 33(9):925-34. PubMed ID: 20948444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
